Denver Health Hospital
Denver, Colorado, 80204, United States
NCT Number: NCT04467996
Intrauterine balloon tamponade (IUBT) is recommended worldwide as the second-line therapy to treat postpartum hemorrhage. While much literature demonstrates the effectiveness of this therapy, little is known about how long the IUBT should be used once placed. Though it is common to use IUBT for 12-24 hours, the balloon may be equally effective when used for shorter durations of time, which could have beneficial effects for patients and hospitals. The proposed study is a pragmatic randomized controlled trial of non-inferiority comparing two durations of time for intrauterine balloon tamponade placement, 6 and 18 hours, in controlling postpartum hemorrhage.
The specific aims of the proposed study are to determine: 1) whether quantitative blood loss significantly differs when the balloon is removed in 6 hours compared to 18 hours, 2) whether hemorrhage-related morbidity differs when the IUBT is kept in place for 6 or 18 hours, and 3) whether shorter duration of IUBT placement has beneficial effects including shortened postpartum hospital stays, improved maternal-infant bonding, and reduced postpartum pain prior to maternal discharge from hospital.
We hypothesize that, once hemorrhage control has been achieved with IUBT placement, there is no clinically significant difference in postpartum blood loss when the balloon is removed 6 hours after placement compared to 18 hours after placement.
This study is active but is not currently recruiting participants.
18 year–55 year
Female
Interventional
Not applicable
Denver, Colorado, 80204, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
Time frame: 18 hours
total blood loss includes output from the intrauterine balloon plus blood loss from sanitary pads
Time frame: during admission
return to the OR, replacement of the IUBT, hysterectomy, pelvic artery embolization
Time frame: during admission
change in hematocrit from admission to discharge
Time frame: during admission
Length of stay in hours
Time frame: during admission
diagnosed postpartum
Time frame: during admission
requiring more than one dose of antibiotics postpartum
Time frame: during admission
after IUBT placement
Time frame: during admission
measured by the mother-to-infant bonding scale (MIBS), scale 0-27, higher score indicates worse maternal-infant bonding
Time frame: during admission
measured by the visual analogue scale (VAS), scale 0-10, higher score indicates worse pain
Denver Health and Hospital Authority
Other
Evaluation of the Minimum Effective Duration of Intrauterine Balloon Tamponade for the Management of Postpartum Hemorrhage: A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07713277
Delayed Cord Clamping, Female Urogenital Diseases and Pregnancy Complications
Vicenza, Italy
View Trial DetailsNCT06452355
Female Urogenital Diseases and Pregnancy Complications, Hemorrhage
Birmingham, Alabama, United States
View Trial DetailsNCT06655207
Female Urogenital Diseases and Pregnancy Complications, Hemorrhage
Denver, Colorado, United States
View Trial DetailsNCT05598502
Female Urogenital Diseases and Pregnancy Complications, Hemorrhage
Kampala, Uganda
View Trial Details